GeneDx Holdings has put up one of the more striking moves in the genomics space this month — up nearly 48% in 30 days and 14.5% in the past week alone to close at $87.41 — yet the short side of the ledger tells a story of conviction rather than capitulation.
The positioning picture is a genuine tension. Short interest has barely shifted, sitting at 21.4% of the free float — a level that classifies as heavily shorted by any measure — and edged up another 1.8% on the week. Bears have held their ground through a sustained rally. That stubbornness looks less alarming when you examine borrow conditions: cost to borrow is running at a modest 0.47%, and availability is loose at over 400% relative to short interest, meaning there are roughly four shares available to borrow for every share currently shorted. There is no mechanical squeeze pressure here. The high short interest reflects a real fundamental debate, not a positioning extreme that is about to snap. Options traders, meanwhile, have shifted clearly bullish — the put/call ratio has dropped to 0.42, well below its 20-day average near 0.59, and close to a one-year low. That combination — stubborn shorts, ample borrow, calls outpacing puts — suggests the two sides of this trade are genuinely dug in.
The Street is broadly on the bull side, though targets have moved around considerably. Following the Q2 earnings print earlier this month, Canaccord Genuity raised its target from $75 to $90 while maintaining Buy. BTIG reiterated Buy at $90. Those moves follow a sharp downward revision cycle in the spring — multiple firms, including Wells Fargo and BTIG, cut targets to the $75–$90 range from prior levels as high as $170 after a guidance miss. The consensus mean target now sits around $90, which is close to where the stock is trading, leaving limited implied upside in the headline number. The valuation picture is stretched: the P/E multiple is above 100x and EV/EBITDA above 70x, though both have compressed meaningfully over the past month as the stock rallied into improving earnings momentum. GeneDx ranks in the 94th percentile on EPS surprise, which is the clearest quantitative support for the bull case — the company has repeatedly beaten estimates. The ORTEX short score of 65 places it only in the 10th percentile of its sector, flagging elevated short positioning relative to peers.
The institutional ownership table adds colour to why this stock carries such polarised positioning. Corvex Management holds 16% of shares, and Casdin Capital — whose founder Eli Casdin sits on the board — holds another 12.4%. Both added materially in Q2, with Corvex adding over 1.5 million shares and Casdin adding 700,000. Goldman Sachs and Morgan Stanley both grew positions over the same period. ARK Investment Management holds roughly 5.3% and also added modestly. The concentration is notable: the top two holders alone account for more than 28% of outstanding shares, which limits the genuine free float available to the short side even as availability numbers look comfortable on paper.
Earnings history adds a final layer of context. The most recent print on August 3 produced a 8.9% next-day gain and a 19.6% move over the following five sessions — the catalyst for much of the current rally. The print before that also produced gains. The next earnings event is scheduled for November 3, which means the market now has roughly ten weeks to decide whether the guidance trajectory has genuinely stabilised or whether the spring's revenue miss was a more durable signal about the business.
The debate into November will turn on whether reimbursement trends for whole genome sequencing are improving as management suggested, and whether the mix shift away from exome testing is compressing margins or expanding the addressable market — the same fundamental disagreement that has kept 21% of the float short even as the stock has nearly doubled off its lows.
See the live data behind this article on ORTEX.
Open WGS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
